UH research team receives grant to fight aggressive pediatric cancer

cancer research

A team of researchers at the University of Houston is working to develop a new treatment for Rhabdomyosarcoma, an aggressive cancer with a higher incidence in young children. Photo via Getty Images.

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

From Your Site Articles
Texas A&M's Dog Aging Project received NIH funding to expand a clinical trial studying how the drug rapamycin can extend the lives of companion dogs. Photo via Getty Images.

Texas A&M expands innovative Dog Aging Project via $7 million grant

pet project

The Texas A&M College of Veterinary Medicine and Biomedical Sciences has received a $7 million grant from the National Institutes of Health to support its Dog Aging Project.

The DAP is a research project that was launched in 2019 by Texas A&M and the University of Washington School of Medicine and has enrolled over 50,000 dogs to date, according to a release. The program studies various breeds of companion dogs and studies the effects of aging to help develop a better understanding of what can lead to an expanded, healthy canine life, which can also assist with human aging knowledge.

The NIH funds will be used to expand a clinical trial studying how the drug rapamycin, also called sirolimus, can extend the lives of companion dogs.

The project, known as Test of Rapamycin In Aging Dogs (TRIAD), is the third DAP clinical trial involving the drug rapamycin. The drug has previously been used as an immunosuppressant during organ transplants in humans. Past DAP studies reported that the drug appears to improve cardiac function in dogs.

“Rapamycin works by modifying the cells’ energy balance and energy handling,” Dr. Kate Creevy, DAP chief veterinary officer and a professor in the VMBS’ Department of Small Animal Clinical Sciences, said in a news release. "It seems to mimic the effects that happen in people or animals who do intermittent fasting. There is a lot of interest in intermittent fasting as a technique that can improve health, particularly healthy aging, and some of the pharmaceutical effects of rapamycin make the same changes at the cellular level.”

So far, 170 dogs are in the trial at 20 sites, with the goal of expanding to 580 dogs enrolled in multiple cities across the country. Dogs must be over 7 years old and in good general health to participate. They should also weigh at least 44 pounds. Owners are required to bring their dogs to one of TRIAD’s participating clinical sites every six months for three years. The Texas clinical sites are in College Station and North Texas.

“Dogs experience many of the age-related cognitive, sensory, neuropathologic and mobility changes that are common in older humans,” Dr. May Reed, a geriatrician at the University of Washington School of Medicine and another primary investigator in the study, said in the release. “The possibility that rapamycin might delay any of the alterations that contribute to cognitive impairment and functional decline is very exciting and has huge translational potential.”

“We get to learn how to support both dog and human aging at the same time. Our research is also powered by owners’ commitments to the health of their dogs, and that’s what makes our work both possible and meaningful,” Creevy added. “We’re very grateful to them.”

Rice researchers are cleaning up when it comes to grants and competitions. Photo via Rice.edu

Rice University innovators claim prizes across health care, energy research

big wins

Undergraduate students from Rice University were awarded the top prize in a health innovation challenge.

Design by Biomedical Undergraduate Teams (DEBUT) Challenge, which is organized by the National Institutes of Health (NIH) and the non-profit organization VentureWell, selected medical device team UroFlo as its winner, claiming the $20,000 prize. The technology, a continuous bladder irrigation system, was recognized for its potential to revolutionize post-operative care and improve patient outcomes.

The winning team from Rice consists of 2024 bioengineering graduates Anushka Agrawal, Sahana Prasanna, Robert Heeter, Archit Chabbi, Kevin Li, and Richard Chan. The UroFlo system provides care to patients after surgery and reduces the burden on health care professionals by implementing state-of-the-art sensors and machine learning algorithms with a touchscreen user interface. This helps with data collection, processing and visualization. UroFlo promises to enhance the management of urinary tract infections (UTIs) and help prevent blood clots.

“We have learned so much from this process and we are really proud of what we have accomplished,” says Chabbi in a news release. “It’s truly rewarding to know that our work can impact patients’ experience and help improve quality of care. Over the many hours we spent working in the Oshman Engineering Design Kitchen (OEDK) at Rice, we’ve not only developed an amazing set of skills, but have also forged really strong connections with one-another and the nearby medical community at the Texas Medical Center.”

The award will be presented on Oct. 25 in Baltimore during the annual Biomedical Engineering Society (BMES) conference.

UroFlo was also with first place in the Johns Hopkins Healthcare Design Competition in the Post-Surgical Infection Management category; first place in the American Society for Artificial Internal Organs Student Design Competition; “Best Medical Device Technology Award” in the 2024 Huff Engineering Design Showcase and competition held by the OEDK; “Outstanding Bioengineering Design Project,” Rice Department of Bioengineering; “Best Presentation” in the Texas Children’s Hospital Surgical Research Day; finalist and “Best Engineering Project” in Rice’s 2024 Shapiro Research Showcases; and semi-finalist in the H. Albert Napier Rice Launch Challenge. UroFlo will continue after Rice, as the project will be developed further.

“We are all very passionate about biomedical engineering, and dedicated and committed to making a difference” Chan said in a news release. “We actually decided to continue to develop UroFlo after our graduation from Rice a few months ago with the hope of improving our innovative solution for urological care.”

In other news, Rice University’s Naomi Halas won $7.5 million over five years from the United States Department of Defense (DOD) Air Force Office of Scientific Research (AFOSR) with her project proposal Multidisciplinary University Research Initiative (MURI) for her project titled “Combining Nonequilibrium Chemistries with Atomic Precision,” which competed in the category “plasmon-controlled single-atom catalysis.”

“Combining Nonequilibrium Chemistries with Atomic Precision” addressed the need for more energy-efficient and less protocol-intensive chemical processes that involve using light to drive chemical reactions and single-atom “reactors” to catalyze chemical reactions that are nearly 100 percent specific in terms of reaction products.

Plasmons work when they make metal nanoparticles act like antennas, and certain designed reactor sites on their surfaces can then carry out chemical reactions at a fraction of the “energy expenditure of conventional industrial catalysts” according to a news release.

Rice University and Baylor College of Medicine have also received $2.8 million in funding from the National Heart, Lung, and Blood Institute (NHLBI) for their research on reducing inflammation and lung damage in acute respiratory distress syndrome (ARDS) patients.

“Cell Based Immunomodulation to Suppress Lung Inflammation and Promote Repair,” will be co-led byRice’s Omid Veiseh, a professor of bioengineering and faculty director of the Rice Biotech Launch Pad, and professor of surgery at Baylor Ravi Kiran Ghanta. They will develop a new translational cell therapy platform “ to allow a better local administration of cytokines to the lungs in order to suppress inflammation and potentially prevent lung damage in ARDS patients” according to a news release.

VenoStent has raised additional funding. Image courtesy of VenoStent

Houston health tech startup secures $20M series A, NIH grant amid clinical trials

fresh funding

A clinical-stage Houston health tech company with a novel therapeutic device has raised venture capital funding and secured a grant from the National Institutes of Health.

VenoStent Inc., which is currently in clinical trials with its bioabsorbable perivascular wrap, announced the closing of a $20 million series A round co-led by Good Growth Capital and IAG Capital Partners. The two Charleston, South Carolina-based firms also led VenoStent's 2023 series A round that closed last year at $16 million.

Additionally, the company secured a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant from NIH, which will help fund its multi-center, 200-patient, randomized controlled trial in the United States.

Tim Boire, VenoStent CEO and co-founder, describes 2024 so far as "a momentous year" so far for his company.

"In the span of a few months, we initiated our first clinical sites, enrolled the first patients in our large RCT and closed our Series A with Norwest," Boire says in a news release. "We also received the NIH grant, which enables us to execute our trial with the highest degree of quality and rigor to make it as scientifically robust and impactful to patients as possible.

'Each of these are major company milestones that collectively represent many years of intensive and fruitful R&D and collaboration," he continues. "These recent milestones will propel our company forward to an exciting next phase."

Tim Boire is the CEO and co-founder of VenoStent. Photo via LinkedIn

The company's innovation, the SelfWrap, goes around arteriovenous (AV) access sites at the time of AV fistula creation surgery. The device is intended "to accelerate the usability and increase the durability of the fistula sites for chronic kidney disease (CKD) patients requiring hemodialysis," reads the release, "mimicking the arterial environment in veins, which experience a 10x increase in pressure and flow during AV creation and causes the veins to become unusable in dialysis."

Along with the investment, VenoStent announced two new board observers. Norwest General Partner Dr. Zack Scott and Investor Dr. Ehi Akhirome are bringing their expertise to the growing company.

"Norwest's investment is tremendous validation for VenoStent, and we are thrilled to have both Zack and Ehi joining the company's board," VenoStent COO and Co-Founder Geoffrey Lucks adds in the release. "Zack and Ehi have extensive knowledge in our space, and their added value will match the capital and cache of Norwest dollar-for-dollar."

Last year at the same time VenoStent announced its last funding round, the SelfWrap was approved by the U.S. Food and Drug Administration to begin its U.S. Investigational Device Exemption (IDE) study.

"Over half a million people in the U.S. rely on hemodialysis to survive and require an arteriovenous fistula creation surgery in order to receive the treatment. However, the AV fistula procedure has a one-year failure rate of more than 60 percent, which significantly impacts patients' survival rates and quality of life," Scott says in the release. "VenoStent's groundbreaking technology for AV fistula formation, SelfWrap, has the potential to significantly improve these odds. We look forward to working with the VenoStent team as it proves the efficacy of this breakthrough technology in order to improve the lives of hundreds of thousands of CKD patients."

Last summer, Boire told InnovationMap on the Houston Innovators Podcast that he's looking to launch the product in 2026.

NeuraStasis, which originated out of the TMC Biodesign program, is launching its latest study in Houston. Photo via Getty Images

Health tech startup launches Houston study improve stroke patients recovery

now enrolling

A Houston-born company is enrolling patients in a study to test the efficacy of nerve stimulation to improve outcomes for stroke survivors.

Dr. Kirt Gill and Joe Upchurch founded NeuraStasis in 2021 as part of the TMC Biodesign fellowship program.

“The idea for the company manifested during that year because both Joe and I had experiences with stroke survivors in our own lives,” Gill tells InnovationMap. It began for Gill when his former college roommate had a stroke in his twenties.

“It’s a very unpredictable, sudden disease with ramifications not just for my best friend but for everyone in his life. I saw what it did to his family and caregivers and it's one of those things that doesn't have as many solutions for people to continue recovery and to prevent damage and that's an area that I wanted to focus myself on in my career,” Gill explains.

Gill and Upchurch arrived at the trigeminal and vagus nerves as a potential key to helping stroke patients. Gill says that there is a growing amount of academic literature that talks about the efficacy of stimulating those nerves. The co-founders met Dr. Sean Savitz, the director of the UTHealth Institute for Stroke and Cerebrovascular Diseases, during their fellowship. He is now their principal investigator for their clinical feasibility study, located at his facility.

The treatment is targeted for patients who have suffered an ischemic stroke, meaning that it’s caused by a blockage of blood flow to the brain.

“Rehabilitation after a stroke is intended to help the brain develop new networks to compensate for permanently damaged areas,” Gill says. “But the recovery process typically slows to essentially a standstill or plateau by three to six months after that stroke. The result is that the majority of stroke survivors, around 7.6 million in the US alone, live with a form of disability that prevents complete independence afterwards.”

NeuraStasis’ technology is intended to help patients who are past that window. They accomplish that with a non-invasive brain-stimulation device that targets the trigeminal and vagus nerves.

“Think of it kind of like a wearable headset that enables stimulation to be delivered, paired to survivors going through rehabilitation action. So the goal here is to help reinforce and rewire networks as they're performing specific tasks that they're looking to improve upon,” Gill explains.

The study, which hopes to enroll around 25 subjects, is intended to help people with residual arm and hand deficits six months or more after their ischemic stroke. The patients enrolled will receive nerve stimulation three times a week for six weeks. It’s in this window that Gill says he hopes to see meaningful improvement in patients’ upper extremity deficits.

Though NeuraStasis currently boasts just its two co-founders as full-time employees, the company is seeing healthy growth. It was selected for a $1.1 million award from the National Institutes of Health through its Blueprint MedTech program. The award was funded by the National Institute of Neurological Disorders and Stroke. The funding furthers NeuraStasis’ work for two years, and supports product development for work on acute stroke and for another product that will aid in emergency situations.

Gill says that he believes “Houston has been tailor-made for medical healthcare-focused innovation.”

NeuraStasis, he continues, has benefited greatly from its advisors and mentors from throughout the TMC, as well as the engineering talent from Rice, University of Houston and Texas A&M. And the entrepreneur says that he hopes that Houston will benefit as much from NeuraStasis’ technology as the company has from its hometown.

“I know that there are people within the community that could benefit from our device,” he says.

Mielad Ziaee, a 20-year-old student at the University of Houston, was tapped for a unique National Institutes of Health program. Photo via UH.edu

Houston student selected for prestigious health care research program

bright future

A Houston-area undergraduate student has been tapped for a prestigious national program that pairs early-career investigators with health research professionals.

Mielad Ziaee was selected for the National Institutes of Health’s 2023-2024 All of Us Research Scholar Program, which connects young innovators with experts "working to advance the field of precision medicine," according to a statement from UH. Ziaee – a 20-year-old majoring in psychology and minoring in biology, medicine and society who plans to graduate in 2025 — plans to research how genomics, or the studying of a person's DNA, can be used to impact health.

“I’ll be one of the ones that define what this field of personalized, precision medicine will look like in the future,” Ziaee said in a statement. “It’s exciting and it’s a big responsibility that will involve engaging diverse populations and stakeholders from different systems – from researchers to health care providers to policymakers.”

Ziaee aims to become a physician who can use an understanding of social health conditions to guide his clinical practice. At a young age, he was inspired to go into the field by his family's own experience.

According to UH, Ziaee is the oldest child of Iranian American immigrants. He saw firsthand the challenges of how language and cultural barriers can impact patients' access to and level of care.

“I think a lot of people define health as purely biological, but a lot of other factors influence our well-being, such as mental health, financial health, and even access to good food, medical care and the internet,” he said in a statement. “I am interested in seeing the relationship among all these things and how they impact our health. So far, a lot of health policies and systems have not really looked beyond biology.”

"I want everyone to have an equal chance to access health care and take charge of their well-being. We need to have the systems in place that let people do that,” he added.

Ziaee is already on his way to helping Houston-based and national health systems and organizations make headway in this area.

He was named as a student regent on the UH System Board of Regents last year, sits on the board of the Houston chapter of the American Red Cross, and is an Albert Schweitzer Fellow.

Last year he was a Centers for Disease Control and Prevention John R. Lewis scholar, for which he presented his research project about predicting food insecurity in pediatric clinical settings and recommendations to improve the assessment based off his summer research with the Johns Hopkins University School of Medicine and the Kennedy Krieger Institute.

Prior to this, he completed a 10-week guided research experience using data visualization and predictive modeling techniques to assess food insecurity in the Third Ward.

“I just took every opportunity that came to me,” Ziaee said. “All my experiences connect with my central desire to increase health access and improve health care. I am very intentional about connecting the dots to my passion.”

Earlier this year, three UH student researchers were named among 16 other early-stage research projects at U.S. colleges and universities to receive a total of $17.4 million from the DOE's Office of Fossil Energy and Carbon Management (FECM). The projects were each awarded between about $750,000 to up to $1.5 million.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

5 Houston innovators who made headlines in August 2025

Featured Innovators

Editor's note: Innovators hailing from both Rice University and University of Houston made headlines in August by developing a new biomaterial that could replace plastic and deploying a new flood scale to help Houstonians stay safe. Plus, one local innovator has a big move on the horizon.

Here are five Houston innovators to know right now.

​M.A.S.R. Saadi and Muhammed Maksud Rahman, Rice University and University of Houston

A team led by M.A.S.R. Saadi and Muhammad Maksud Rahman has developed a biomaterial that they hope could be used for the “next disposable water bottle." Photo courtesy Rice University.

Collaborators from two Houston universities are leading the way in engineering a biomaterial into a scalable, multifunctional material that could potentially replace plastic. The research was led by Muhammad Maksud Rahman, an assistant professor of mechanical and aerospace engineering at the University of Houston and an adjunct assistant professor of materials science and nanoengineering at Rice University. M.A.S.R. Saadi, a materials science and nanoengineering doctoral student at Rice University, was first author on the study. The study introduced a biosynthesis technique that aligns bacterial cellulose fibers in real-time, which resulted in robust biopolymer sheets with “exceptional mechanical properties,” according to the researchers. Learn more.

Paul Cherukuri, Rice University

Paul Cherukuri, Rice’s first vice president for innovation and chief innovation officer, will leave his post next month. Photo via Rice.edu

Paul Cherukuri, Rice University's top innovation executive, responsible for some of Rice’s major innovative projects like the Rice BioTech LaunchPad and Rice Nexus, will leave the university at the end of September to accept a position at the University of Virginia. Cherukuri, Rice’s first vice president for innovation and chief innovation officer, will become the University of Virginia’s Donna and Richard Tadler University Professor of Entrepreneurship and the school's first chief innovation officer. Learn more.

Steven Paul Woods (pictured) and Natalie C. Ridgely, University of Houston

Steven Paul Woods, professor of Psychology, at UH. Photo courtesy of UH

University of Houston Professor of Psychology Steven Paul Woods and doctoral student Natalie C. Ridgely recently partnered with the Space City Weather (SCW) blog to create a new flood alert scale for the trusted weather site. “My lab does work on how people access, understand, and use health information, so I thought we could adapt some of that ongoing work and our expertise in psychological science to answer questions about weather communication, and help keep Houstonians informed and safe,” said Woods. Learn more.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”

View All Listings